This study is looking at new ways to predict how pulmonary fibrosis (scarring of the lungs) will progress in people with certain types of interstitial lung disease (ILD). Researchers are testing two imaging techniques: a PET scan using [68Ga]CBP8 and an MRI using Gadoterate Meglumine. They want to see if these scans can help identify who will experience worsening lung disease over time. You may be able to join if you are between 18 and 80 years old, have chronic hypersensitivity pneumonitis, connective tissue-associated ILD, or undifferentiated ILD, and are on stable immunosuppression treatment. The study aims to enroll 60 participants. The study's success will be measured by how well these imaging methods predict the development of progressive pulmonary fibrosis over 24 months.

Study design

This interventional study plans to enroll 60 participants. It is not specified if it is randomized or blinded.

What's involved

Participants will receive a single intravenous injection of [68Ga]CBP8 and a single intravenous injection of Gadoterate Meglumine. They will undergo combined PET and MRI scans at the beginning of the study.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 24 months to assess the development of progressive pulmonary fibrosis.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.